Oleg Gluz, MD, Evang. Krankenhaus “”Bethesda”” Klinik, Mönchengladbach, Germany, explains why it can be difficult to define which breast cancer patients are ‘high-risk’ and discusses the need for new biomarkers. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.